Eli Lilly and Compan

LLY
Delayed Nyse - 07/19 10:01:32 pm
106.79USD
-1.43%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 2018 2019 (e)
Sales 24 556 22 171
EBITDA 7 829 7 519
Operating profit (EBIT) 6 766 6 243
Pre-Tax Profit (EBT) 3 796 5 262
Net income 3 232 8 126
P/E ratio 37,0x 12,1x
EPS ( $ ) 3,13 8,80
Dividend per Share ( $ ) 2,25 2,53
Yield 1,94% 2,36%
Reference price ( $ ) 115,720 106,790
Announcement Date 02/06/2019
11:25am
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 2018 2019 (e)
Debt 4 685 3 031
Finance - -
Operating income (EBITDA) 7 829 7 519
Leverage
(Debt/EBITDA)
0,60x 0,40x
Capital Expenditure 1 211 1 157
Book Value Per Share (BVPS) ( $ ) 9,29 8,02
Cash Flow per Share ( $ ) 5,34 7,39
Announcement Date 02/06/2019
11:25am
-
Balance Sheet Analysis
Financial Ratios
Size 2019e 2020e
Capitalization 98 336 M $ -
Entreprise Value (EV) 101 366 M $ 105 975 M $
Valuation 2019e 2020e
P/E ratio (Price / EPS) 12,1x 17,4x
Capitalization / Revenue 4,44x 4,15x
EV / Revenue 4,57x 4,28x
EV / EBITDA 13,5x 12,0x
Yield (DPS / Price) 2,36% 2,55%
Price to book (Price / BVPS) 13,3x 10,8x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) 28,2% 30,3%
Operating Leverage (Delta EBIT / Delta Sales) -0,80x 2,20x
Net Margin (Net Profit / Revenue) 36,7% 22,9%
ROA (Net Profit / Asset) 11,9% 15,1%
ROE (Net Profit / Equities) 80,3% 69,2%
Rate of Dividend 28,7% 44,2%
Balance Sheet Analysis 2019e 2020e
CAPEX / Sales   5,22% 5,03%
Cash Flow / Sales 30,7% 29,5%
Capital Intensity (Assets / Sales) 3,08x 1,51x
Financial Leverage (Net Debt / EBITDA) 0,40x 0,90x
Price Earning Ratio
BNA & Dividende